IQT0 Stock Overview
A clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Inhibikase Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.50 |
| 52 Week High | US$3.33 |
| 52 Week Low | US$0.84 |
| Beta | 1.12 |
| 11 Month Change | 13.64% |
| 3 Month Change | 98.41% |
| 1 Year Change | 199.29% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -24.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| IQT0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -1.3% |
| 1Y | 199.3% | -17.5% | 7.4% |
Return vs Industry: IQT0 exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: IQT0 exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| IQT0 volatility | |
|---|---|
| IQT0 Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IQT0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IQT0's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 9 | Milton Werner | www.inhibikase.com |
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
Inhibikase Therapeutics, Inc. Fundamentals Summary
| IQT0 fundamental statistics | |
|---|---|
| Market cap | €129.68m |
| Earnings (TTM) | -€18.79m |
| Revenue (TTM) | €0.96 |
Over9,999x
P/S Ratio-6.9x
P/E RatioIs IQT0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IQT0 income statement (TTM) | |
|---|---|
| Revenue | US$1.00 |
| Cost of Revenue | US$13.62m |
| Gross Profit | -US$13.62m |
| Other Expenses | US$5.95m |
| Earnings | -US$19.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | -1,361,834,700.00% |
| Net Profit Margin | -1,956,524,900.00% |
| Debt/Equity Ratio | -13.5% |
How did IQT0 perform over the long term?
See historical performance and comparison